openPR Logo
Press release

Nonalcoholic Steatohepatitis Therapeutics Detail Industrial and Market studies (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global 2015 - 2025

09-05-2017 12:34 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Press-Release

Nonalcoholic Steatohepatitis Therapeutics Detail Industrial

"Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified, however obesity and insulin resistance are believed to have major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its function. Though, NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time.

Over a period of ten years up to 20% of patients with NASH develop cirrhosis of the liver, and 10% die from the disease. At present, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are now considered as the leading cause of liver disease in Western countries. Thus, there is an urgent need for effective treatment options for these diseases. The need for treatment is expected to propel the growth of NASH therapeutics in coming years. 

Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=718456

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report provides a list of the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market followed by Obeticholic Acid (OCA) market and the market for Elafibranor is expected to grow at the highest CAGR. 

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes epidemiology of Nonalcoholic steatohepatitis (NASH) by region, to provide a thorough analysis of the overall addressable global market for the NASH therapeutics. Moreover, the report provides qualitative information about diagnosis and treatment of NASH. 

The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the NASH market across different regions worldwide. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. 

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.). 

The Nonalcoholic Steatohepatitis (NASH) Therapeutics market has been segmented as follows: 

-- Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type
Overview
Potential Drug Candidates in Phase III
Obeticholic Acid (OCA)
Aramchol (arachidyl amido cholanoic acid)
Saroglitazar
Elafibranor 

-- Table of Contents

Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Global NASH Market, by Drug, 2025 (US$ Mn)

Chapter 3 Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market Overview 
3.1 Introduction
3.2 Epidemiology of Nonalcoholic Steatohepatitis (Qualitative Analysis)
3.2.1 North America
3.2.2 Europe
3.2.3 Asia Pacific
3.2.4 Rest of World
3.3 Diagnosis and Treatment of NASH (Qualitative Analysis)
3.4 Market Dynamics
3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities

Chapter 4 Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type, 2015 – 2025 (US$ Mn)
4.1 Overview
4.2 Potential Drug Candidates in Phase III
4.2.1 Obeticholic Acid (OCA)
4.2.2 Aramchol (arachidyl amido cholanoic acid)
4.2.3 Saroglitazar
4.2.4 Elafibranor
4.3 Pipeline Analysis
4.3.1 Tabular Representation of Phase I and Phase II Clinical Trials (Qualitative Analysis)
4.4 Target Population By Geography: NASH Market 

Chapter 5 Recommendations

Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.1.1 Company Overview
6.1.2 Financial Overview
6.1.3 Product Pipeline
6.1.4 Business Strategies
6.1.5 Recent Developments
6.2 Intercept Pharmaceuticals Inc.
6.3 Galmed Pharmaceuticals
6.4 GENFIT SA 
6.5 Gilead Sciences Inc. 
6.6 Zydus Cadila 
6.7 Immuron Ltd. 
6.8 Conatus Pharmaceuticals 

Full Report @ http://www.researchmoz.us/nonalcoholic-steatohepatitis-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2025-report.html

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Steatohepatitis Therapeutics Detail Industrial and Market studies (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global 2015 - 2025 here

News-ID: 698751 • Views:

More Releases from Press-Release

GLOBAL AUTOMATED TELLER MACHINE MARKET 2019-2025 | Competitive Major Vendors - NCR, Diebold, Wincor Nixdorf International, GRG Banking Equipment
GLOBAL AUTOMATED TELLER MACHINE MARKET 2019-2025 | Competitive Major Vendors - N …
Latest Update "GLOBAL AUTOMATED TELLER MACHINE MARKET 2019-2025 | Competitive Major Vendors - NCR, Diebold, Wincor Nixdorf International, GRG Banking Equipment" with Edition 2019 Survey of Related Topic (Industries / Pharmaceutical / Retail / Equipments / Energy / ICT) : Global Current Growth and Future. ' ' An automated teller machine, or an ATM, is a cash vending machine that is operated by financial institutions and allows customers to perform financial transactions
GLOBAL AUTOMATED STEERING WHEEL MARKET 2019-2025 | Competitive Major Vendors - Autoliv, JTEKT, Nexteer Automotive, ZF Friedrichshafen
GLOBAL AUTOMATED STEERING WHEEL MARKET 2019-2025 | Competitive Major Vendors - A …
Latest Update "GLOBAL AUTOMATED STEERING WHEEL MARKET 2019-2025 | Competitive Major Vendors - Autoliv, JTEKT, Nexteer Automotive, ZF Friedrichshafen" with Edition 2019 Survey of Related Topic (Industries / Pharmaceutical / Retail / Equipments / Energy / ICT) : Global Current Growth and Future. ' ' Automated steering wheel (also called a driving wheel or a hand wheel) is a type of steering control in vehicles and vessels (ships and boats). The steering
GLOBAL AUTOMATED MINE SCANNING MACHINES MARKET 2019-2025 | Competitive Major Vendors - 3D-Laser Mapping, Airware, Clearpath Robotics, Clickmox
GLOBAL AUTOMATED MINE SCANNING MACHINES MARKET 2019-2025 | Competitive Major Ven …
Latest Update "GLOBAL AUTOMATED MINE SCANNING MACHINES MARKET 2019-2025 | Competitive Major Vendors - 3D-Laser Mapping, Airware, Clearpath Robotics, Clickmox" with Edition 2019 Survey of Related Topic (Industries / Pharmaceutical / Retail / Equipments / Energy / ICT) : Global Current Growth and Future. ' ' Automated mine scanning machines are equipped with a vision system and advanced sensor fusion technology. This advancement in technology makes the machines efficient to be incorporated
GLOBAL BATCH CODING MACHINES MARKET 2019-2025 | Competitive Major Vendors - Videojet, Markem-Imaje, Weber Marking, Zanasi, Squid Ink Manufacturing
GLOBAL BATCH CODING MACHINES MARKET 2019-2025 | Competitive Major Vendors - Vide …
Latest Update "GLOBAL BATCH CODING MACHINES MARKET 2019-2025 | Competitive Major Vendors - Videojet, Markem-Imaje, Weber Marking, Zanasi, Squid Ink Manufacturing" with Edition 2019 Survey of Related Topic (Industries / Pharmaceutical / Retail / Equipments / Energy / ICT) : Global Current Growth and Future. ' ' Batch coding machines are used in pharmaceutical & other packaging industries The global Batch Coding Machines market is valued at xx million US$ in 2018

All 5 Releases


More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will